Japan colorectal tumor prevention study: clinical trial by low-dose aspirin(100 mg/day) - Japan colorectal tumor prevention study: clinical trial by low-dose aspirin (J-CAPP Study II)

Ishikawa Hideki0 个研究点目标入组 4,500 人开始时间: 2019年3月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Candidate patients have to meet all the following inclusion criteria to participate in the study.
•# Patients with at least one colorectal tumor (intramucosal cancer and adenoma) as confirmed by histological diagnosis, all of which have been removed endoscopically including the past.
•# Patients with known history of all endoscopic treatments (including histological diagnosis) of colorectal tumors. Patients without histological diagnosis but have histological sections could participate in the trial.
•# Patients who have undergone total colonoscopy at least twice.
•# Patients with clean colon as confirmed by total colonoscopy within 3 months before the study. All histological diagnosis of the colorectal polyps should be done before the trial start.

•# Patients with a medical history of submucosal (sm) or deeper colorectal cancer.
•# Patients with familial adenomatous polyposis or Lynch syndrome.
•# Patients currently taking antithrombotics such as Bayaspirin, Panaldine, Warfarin and Persantin etc.
•# Patients with known allergy to aspirin.
•# Patients who have undergone colorectal resection (those who have undergone appendectomy are allowed to participate in the study).
•# Women who are or may be pregnant during the study period.
•# Patients with a history of treatment of gastric or duodenal ulcer (those with successful eradication of Helicobacter pylori and ulcer resolution at S2 are allowed to participate in the study)
•# Patients with inflammatory bowel disease (ulcerative colitis, Crohn syndrome), bleeding diverticulosis, bleeding gastritis.
•# Patients with bleeding tendency, a platelet count of < 100,000 /mm3, or with abnormal prothrombin time.
•# Patients with any existing cancer at the time of participation in the study.
•# Patients currently taking anticancer drugs.
•# Patients currently taking NSAIDs at least 3 times weekly, for example, as a analgesic.

发起方

Ishikawa Hideki